In a complaint, the FTC said the deal would maintain Sanofi’s monopoly over treatments for Pompe disease. Maze Therapeutics Inc and Sanofi announced a deal for the Pompe disease program MZE001 in May.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results